



SciFINDER[®]
A CAS SOLUTION

SciFinder

Chemical Abstracts Service
tkhristova@acs-i.org



SciFINDER[®]
A CAS SOLUTION

Chemical Abstracts Service





CAS is a division of the American Chemical Society.
Copyright 2016 American Chemical Society. All rights reserved.

CAS

- 1907
- 1,400 CAS,
- 50
- 10,000
- 63
- *Chemical Abstracts*
- 2,500 , 500
- - ,

CAS

,



CAS

.

CAS is a division of the American Chemical Society.
Copyright 2017 American Chemical Society. All rights reserved.



CAS

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Office

(43) International Publication Date
12 June 2018 (2018/0602)

PCT

(11) International Publication Number
WO 02/46157 A2

(51) International Classifications: C07D 211/00
(52) International Application Number: PCT/US 02/077
(53) International Filing Date: 1 December 2001 (2001.12.01)
(54) Filing Language: English
(55) Publication Language: English
(56) Priority Data: 60/231,216 (December 2000 US); 122,841 (US); 60/252,600 (December 2001 US)
(57) Applicant: BERACON, INC. (US); 111 Lusk Avenue, Pittsburgh, PA 15203, USA
(58) Inventors: WU, YUAN (The Royal Canal Hotel, Malton, York, YO10 5AA, UK); BANISTER, Thomas B. (120 Ocean Street, Scarborough, MA 01820 (US)); KLEIN, Gregory D. (100 Tower Street #201, Boston, MA 02110 (US))
(59) Agent: GORHAM, Barry M. (1111 Park Avenue, Suite 1000, Boston, MA 02128 (US))
(60) Designated States (Advocate): AE, AG, AL, AM, AN, AR, AT, AU, BA, BB, BG, BR, CA, CH, CN, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GR, HU, IL, IN, JP, KE, KR, KZ, LI, LU, LV, MA, MD, ME, MG, MK, MN, MU, MV, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SR, TH, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VN, YU, ZA, ZM, ZW

(64) Title: METHODS FOR THE STEREOSLECTIVE SYNTHESIS OF SUBSTITUED TEREBENES

Examples of Substituted Terebenes Available for the Practice of the Present Invention

Structure A: C1=CC=C(C=C1)C2=CC=CC=C2
Structure B: C1=CC=C(C=C1)C2=CC=CC=C2C
Structure C: C1=CC=C(C=C1)C2=CC=CC=C2C
Structure D: C1=CC=C(C=C1)C2=CC=CC=C2C

WO 02/46157 A2



23 нових речовин

153 реакцій

3 структур Маркуша



27 одностадійних реакцій

42 відомих речовин з новою інформацією

6 нових концепцій



SciFinder



CAS

-
-
-
-
-
-
-
-
-

-
-
-
-
-
-
-



100



CAS Source Index (CASSI) Search Tool

CAS Source Index (CASSI) Search Result

CAS Source Index (CASSI) Search Result


Displaying Record for Publication: [Ukrainica Bioorganica Acta](#)

Entry Type	Active Serial
Title	Ukrainica Bioorganica Acta
Abbreviated Title	Ukr. Bioorg. Acta
CODEN	UBAKAL
ISSN	1814-9766
Language of Text	English
Summaries In	English
History	v1 n1/2 2004+
Publication Notes	Avail. from Internet at URL: htt
Publisher Name	Institut Molekulyarnoi Biologii

Displaying Record for Publication: [Zhurnal Klinichnikh ta Eksperimental'nikh Medichnikh Doslidzhen](#)



Entry Type	Active Serial
Title	Zhurnal Klinichnikh ta Eksperimental'nikh Medichnikh Doslidzhen
Abbreviated Title	Zh. Klin. Eksp. Med. Dosl.
Translated Title	Journal of Clinical and Experimental Medical Research
CODEN	ZKEMBU
ISSN	2310-2209
Language of Text	English
Summaries In	English
History	v1 n1 2013+
Publication Notes	Avail. from Internet at URL: http://ujcem.med.sumdu.edu.ua/en/
Publisher Name	Sums'kii Derzhavnii Universitet, Medichnii Institut
Alternate Title(s)	Journal of Clinical and Experimental Medical Research
Abbreviated Alternate Title(s)	J. Clin. Exp. Med. Res.

-
-
-
-




-
-
-


Information added to the CAS databases annually since 2000



Original publication languages in CAS databases



Source: Research, Nature(2016): Nature Salary and job satisfaction survey



Source: CAS Global Customer Satisfaction Survey



SciFinderⁿ -

CAS

- CAS-
- ,
- CAS

SciFinderⁿ



The screenshot displays the SciFinder web interface with the search term "treatment of cancer". The interface is divided into several sections:

- Search Panel (Left):** Includes filters for "All", "Substances", "Reactions", "References", and "Suppliers". It also shows "Recent Searches" for dates like March 28, 2017, and March 27, 2017.
- Structure Match Panel (Top Left):** Shows "As Drawn (5)" and "Substructure (18)".
- Filter by Panel (Middle Left):** Includes "Substance Role" (Product: 13, Reactant: 5), "Yield" (90-100%: 4, 80-89%: 2, 70-79%: 4, 50-69%: 1, 30-49%: 2), "Number of Steps" (1: 13), "Experimental Protocols" (MethodsNow Available: 2, Procedure Available: 6), "Reaction Type", "Reagent", "Catalyst", "Solvent", "Commercial Availability", and "Reaction Notes".
- Source Reference Panel (Bottom Left):** Includes "Publication Year", "Document Type", and "Language".
- Reactions Panel (Middle):** Shows "Scheme 1 (2 Reaction)" with a chemical structure and "Suppliers (3)".
- References Panel (Right):** Shows "References (3,103)" with filters for "Substances", "Reactions", and "Cited By". It lists two references:
 - Multikinase inhibitors: a new option for the treatment of thyroid cancer** by Gild, Matti L.; Bullock, Martyr; Robinson, Bruce G.; Clifton-Bligh, Roderick. *Nature Reviews Endocrinology* (2011), 7(10), 617-624. Language: English, Database: CAplus. Abstract: A review. Preclin. models have shown that inhibition of kinases in mitogenic and angiogenic signaling pathways can have antitumoral effects. Starting with a brief synopsis of a malignancy that responds well to kinase inhibition (chronic myeloid leukemia) compared with one with less durable responses as yet (melanoma), this Review highlights challenges that must be overcome in order to successfully translate small-mol. therapies to thyroid cancer in the future. Thyroid Cancer typically has a good outcome following standard treatment which include surgery, radiotherapy, iodine ablation and TSHR.
 - sorafenib for the treatment of renal cancer** by Strumberg, Dirk. *Expert Opinion on Pharmacotherapy* (2012), 13(3), 407-419. Language: English, Database: CAplus. Abstract: A review. Introduction: was the first oral antiangiogenic multikinase inhibitor (Raf kinases, VEGF receptors 1 - 3, PDGF-beta, Flt-3, c-kit) for advanced renal cell carcinoma (RCC) to be approved. Since 2005, a total of six drugs have been approved for the treatment of RCC. Areas covered: The prelin. and clin. development of sorafenib that led to its approval for advanced RCC is reviewed in this paper. Its safety, tolerability and efficacy are summarized and compared with other approved treatment options for RCC. Real-world data on clinical response, adverse events and combination trials with it.
- Structure Match Panel (Top Right):** Shows "As Drawn (3,103)" and "Substructure (3,290)".
- Filter by Panel (Middle Right):** Includes "Document Type" (Journal: 1,955, Patent: 1,132, Review: 572, Conference: 13, Dissertation: 3), "Language" (English: 2,765, Chinese: 194, Japanese: 64, Korean: 40, French: 24), and "Publication Year" (Bar chart showing an increasing trend from 1980 to 2010).

CAS



47 50

1



21 25

2



49 50

3



98 100

4

1. Pharm Exec's Top 50 Companies 2017 <http://www.pharmexec.com/pharm-execs-top-50-companies-2017>
2. The Top Biotech Companies of 2017 <https://www.genengnews.com/the-lists/top-25-biotech-companies-of-2017/77901002>
3. C&EN's Global Top 50 <https://cen.acs.org/articles/95/i30/CENs-Global-Top-50.html>
4. ShanghaiRanking's Global Ranking of Academic Subjects 2017 – Chemistry <http://www.shanghairanking.com/Shanghairanking-Subject-Rankings/chemistry.html>

CAS is a division of the American Chemical Society.
Copyright 2018 American Chemical Society. All rights reserved.



SCIFINDER
A CAS SOLUTION

CAS
TKhristova@acs-i.org

Connect with SciFinder



Дякую!!!

- CAS

—

CAS

...

- ...

,

,

...

—

CAS

- ...

-

